Alzheimer dementia: Starting, stopping drug therapy.
| Autor: | Kim LD; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.; Center for Geriatric Medicine, Medicine Institute, Cleveland Clinic, Cleveland, OH, USA. kiml2@ccf.org., Factora RM; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.; Center for Geriatric Medicine, Medicine Institute, Cleveland Clinic, Cleveland, OH, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cleveland Clinic journal of medicine [Cleve Clin J Med] 2018 Mar; Vol. 85 (3), pp. 209-214. |
| DOI: | 10.3949/ccjm.85a.16080 |
| Abstrakt: | Alzheimer disease is the most common type of dementia. Two classes of cognition-enhancing drugs are approved to treat the symptoms, and both have provided modest benefit in clinical trials. Psychotropic drugs are sometimes used off-label to treat behavioral symptoms of Alzheimer disease. All these medications should be continuously evaluated for clinical efficacy and, when appropriate, discontinued if the primary benefit--preservation of cognitive and functional status and a reduction in behaviors associated with dementia--is no longer being achieved. (Copyright © 2018 Cleveland Clinic.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|